Xoma

XOMA

Market cap $452M

Overview Fund Activity

37.42 USD

-0.30

0.8%

At close Updated Sep 12, 4:00 PM EDT

1 day

-0.8%

5 days

5.98%

1 month

31.48%

3 months

52.11%

6 months

76.84%

Year to date

43.92%

1 year

34.75%

5 years

78.7%

10 years

120.9%

About: XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.

Employees: 13

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

233% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 9

85% more call options, than puts

Call options by funds: $37K | Put options by funds: $20K

50% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]

31% more capital invested

Capital invested by funds: $156M [Q1] → $206M (+$49M) [Q2]

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

2.79% more ownership

Funds ownership: 65.54% [Q1] → 68.32% (+2.79%) [Q2]

2% more funds holding

Funds holding: 64 [Q1] → 65 (+1) [Q2]

See Fund Rankings

Financial journalist opinion

Based on 5 articles about XOMA published over the past 30 days

Zacks Investment Research

Wall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should Know

The mean of analysts' price targets for XOMA Royalty (XOMA) points to an 86.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should Know

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

EMERYVILLE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will present a company update at the H.C. Wainwright 27th Annual Global Investment Conference.

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

Zacks Investment Research

Here's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock Now

After losing some value lately, a hammer chart pattern has been formed for XOMA Royalty (XOMA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock Now

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

WALTHAM, Mass. and DUBLIN and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator (“XOMA Royalty”), announced today they have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty (“Sub”), has agreed to acquire the entire issued and to be issued share capital of Mural for cash (the “Acquisition”) subject to the satisfaction of the closing conditions set out in Appendix I of this Announcement (the “Conditions”), including approval by Mural Shareholders. Following a strategic review process, the Mural board of directors (the “Mural Board”) determined the acquisition and cash offer by XOMA Royalty is in the best interests of all Mural Shareholders and has approved the Acquisition. The Acquisition has also been approved by the boards of directors of XOMA Royalty and Sub.

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

Zacks Investment Research

How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15%

The average of price targets set by Wall Street analysts indicates a potential upside of 106.2% in XOMA Royalty (XOMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15%

Zacks Investment Research

XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates

XOMA Royalty (XOMA) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to a loss of $0.28 per share a year ago.

XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

Business development : Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty's recently announced acquisition of LAVA Therapeutics.

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of HilleVax, Inc. (NasdaqGS: HLVX) to XOMA Royalty Corporation (NasdaqGM: XOMA). Under the terms of the proposed transaction, shareholders of HilleVax will receive $1.95 in cash per share, plus one non-transferable contingent value right, representing the right to receive additional payments under cert.

HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.

NEW YORK , Aug. 5, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by HilleVax, Inc. (NASDAQ: HLVX) and its board of directors concerning the proposed acquisition of the company by XOMA Royalty Corporation (NASDAQ: XOMA). Stockholders will receive $1.95 in cash and one contingent value right for each share of HilleVax stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V.

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

See News Rankings

Charts implemented using Lightweight Charts™